Eli Lilly and Company (ETR:LLY)
Germany
· Delayed Price · Currency is EUR | Market Cap | 610.16B |
| Revenue (ttm) | 45.34B |
| Net Income (ttm) | 10.28B |
| Shares Out | n/a |
| EPS (ttm) | 11.37 |
| PE Ratio | 59.38 |
| Forward PE | 31.67 |
| Dividend | 5.18 (0.76%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 1,586 |
| Average Volume | 3,054 |
| Open | 678.10 |
| Previous Close | 679.30 |
| Day's Range | 668.20 - 683.40 |
| 52-Week Range | 604.60 - 888.30 |
| Beta | 0.39 |
| RSI | 46.93 |
| Earnings Date | Aug 7, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Eli Lilly seen as the stronger bet amid escalating competition with Novo in India
The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India, one of the fastest-growing pharmaceutical frontiers. As rising obesity an...
Eli Lilly to bring Mounjaro pen in India to rival Novo Nordisk’s Wegovy
Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy
Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk...
Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate
Weight loss and diabetes jabs linked to potentially fatal side effect
Weight loss and diabetes jabs taken by more than a million people in the UK have been linked to a potential serious side effect, with some deaths, according to data from the UK medicines regulator.
US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows
Although glucagon-like peptide-1 (GLP-1) agonists have shown promising results in reducing weight and cardiovascular risks, new data reveals that many U.S. adults struggle to stay on long-term treatme...
Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.
What's Going On With Viking Therapeutics Stock On Wednesday?
Viking Therapeutics, Inc. (NASDAQ: VKTX) on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-depende...
Eli Lilly's olomorasib granted orphan drug designation for NSCLC type
Novo Nordisk’s Wegovy debuts in India: How it works, who it’s for, and how much it costs
Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy is a once-weekly injectable using a user-friendly FlexTouch pen. Targetin...
Abbott jumps on RFK Jr. health push plus, reviews of Eli Lilly's obesity drug data
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Novo Nordisk rolls out weight loss drug Wegovy in India, following Eli Lilly’s Mounjaro launch
Eli Lilly: It Is A Bet On Human Longevity
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Eli Lilly declares $1.50 dividend
Lilly declares third-quarter 2025 dividend
INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common ...
Eli Lilly drug bimagrumab saves muscle mass when added to Novo's Wegovy
Eli Lilly's Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns
Eli Lilly And Co (NYSE: LLY) on Saturday announced detailed results from the ACHIEVE-1 Phase 3 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control...
NHS begins mass rollout of weight-loss jabs to patients in England
About 220,000 patients expected to receive Mounjaro over three years as GPs can prescribe the drugs for the first time Thousands of patients in England will be able to access weight-loss jabs via thei...
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora f...
Notable healthcare headlines for the week: Eli Lilly, Novavax and Sarepta Therapeutics in focus
Key deals this week: Couchbase, Eli Lilly, NTT Data, QXO, US Steel and more
Eli Lilly posts detailed late-stage trial data for oral weight loss drug orforglipron
Lilly expects orforglipron obesity results in third quarter
Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the drug...